Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/21031

TDMS Study 96003-03 Pathology Tables

NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01
Route: GAVAGE                                                                                                     Time: 09:19:00

                                                          FINAL#1/MICE




       Facility:  BIORELIANCE

       Chemical CAS #:  106-95-6

       Lock Date:  10/18/00

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include 008    VEHICLE CONTROL
                               Include 009    0.5     MG/KG
                               Include 010    1 MG/KG
                               Include 011    2 MG/KG
                               Include 012    4 MG/KG
                               Include 013    8 MG/KG
                               Include 001    VEHICLE CONTROL
                               Include 002    0.5     MG/KG
                               Include 003    1 MG/KG
                               Include 004    2 MG/KG
                               Include 005    4 MG/KG
                               Include 006    8 MG/KG























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Dosing Accident                                    2                                                                            
    Moribund Sacrifice                                 2            3            4            6            1            3           
    Natural Death                                      2            2            3            1            3                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                 9           10            8            8           11           12           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (14)         (15)         
      Leukemia Erythrocytic                                         1 (7%)                                                          
      Lymphoma Malignant                               2 (13%)      1 (7%)                    1 (7%)                                
   Salivary Glands                                                              (3)                                                 
      Duct, Carcinoma                                                            3 (100%)                                           
   Stomach, Forestomach                               (14)         (15)         (12)         (13)         (14)         (15)         
      Squamous Cell Papilloma                          5 (36%)      8 (53%)      4 (33%)      7 (54%)      5 (36%)      6 (40%)     
      Squamous Cell Papilloma, Multiple                3 (21%)      2 (13%)      2 (17%)                   2 (14%)      4 (27%)     
   Tooth                                              (2)          (3)          (6)          (7)          (3)          (3)          
      Odontogenic Tumor                                2 (100%)     3 (100%)     6 (100%)     6 (86%)      2 (67%)      3 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                                           (1)                       (1)                                    
      Lymphoma Malignant                                            1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (13)         (14)         (12)         (13)         (12)         (15)         
      Lymphoma Malignant                                            1 (7%)                                                          
   Adrenal Medulla                                    (13)         (14)         (12)         (12)         (12)         (15)         
      Lymphoma Malignant                                            1 (7%)                                                          
   Pituitary Gland                                    (11)         (14)         (14)         (13)         (14)         (14)         
      Lymphoma Malignant                                                                      1 (8%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (13)         (15)         (14)         (14)         (13)         (15)         
      Lymphoma Malignant                               1 (8%)       1 (7%)                                                          
   Uterus                                             (13)         (15)         (13)         (14)         (12)         (15)         
      Lymphoma Malignant                                            1 (7%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node, Mesenteric                             (13)         (14)         (12)         (15)         (12)         (15)         
      Lymphoma Malignant                                            1 (7%)                                                          
   Lymph Node, Mediastinal                            (14)         (15)         (14)         (14)         (12)         (14)         
      Lymphoma Malignant                                            1 (7%)                                                          
   Spleen                                             (15)         (14)         (15)         (15)         (13)         (15)         
      Leukemia Erythrocytic                                         1 (7%)                                                          
      Lymphoma Malignant                               2 (13%)      1 (7%)                    1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (14)         (15)         
      Squamous Cell Papilloma                          1 (7%)       1 (7%)       3 (20%)      3 (20%)      5 (36%)      1 (7%)      
      Squamous Cell Papilloma, Multiple                                                                    1 (7%)                   
      Dermis, Fibrosarcoma                                                                                              1 (7%)      
      Lip, Squamous Cell Papilloma                     1 (7%)       1 (7%)                                 1 (7%)       3 (20%)     
      Vulva, Squamous Cell Papilloma                   2 (13%)      4 (27%)      1 (7%)       5 (33%)      4 (29%)      6 (40%)     
      Vulva, Squamous Cell Papilloma, Multiple                                                1 (7%)       1 (7%)       1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (14)         (15)         (15)         (15)         (14)         (15)         
      Alveolar/Bronchiolar Adenoma                                                            2 (13%)                               
      Alveolar/Bronchiolar Carcinoma                                                                                    1 (7%)      
      Lymphoma Malignant                                            1 (7%)                    1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                                                                                     (1)          
      Adenoma                                                                                                           1 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (14)         (14)         (15)         (13)         (15)         
      Lymphoma Malignant                               1 (7%)       1 (7%)                    1 (7%)                                
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                                         1 (7%)                                                          
      Lymphoma Malignant                               2 (13%)      1 (7%)                    1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            10          13          10          14          11          14               
     Total Primary Neoplasms                           16          21          19          25          21          27               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  9          10           8           9          11          14               
     Total Benign Neoplasms                            12          16          10          18          19          22               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               2           2           3           1                       2               
     Total Malignant Neoplasms                          2           2           3           1                       2               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  2           3           6           6           2           3               
     Total Uncertain Neoplasms                          2           3           6           6           2           3               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 2            2            3            2            4            1           
    Natural Death                                      1            3            3                         4            2           
    Dosing Accident                                                 1                         1            1            1           
  Survivors                                                                                                                         
    Terminal Sacrifice                                12            9            9           12            6           11           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (14)         (15)         (14)         (15)         (14)         (15)         
      Leukemia Erythrocytic                                                      1 (7%)                    1 (7%)       1 (7%)      
   Salivary Glands                                                 (1)          (1)          (1)                                    
      Duct, Carcinoma                                               1 (100%)     1 (100%)     1 (100%)                              
   Stomach, Forestomach                               (15)         (14)         (14)         (15)         (13)         (14)         
      Squamous Cell Papilloma                          5 (33%)      3 (21%)      5 (36%)      5 (33%)      5 (38%)      5 (36%)     
      Squamous Cell Papilloma, Multiple                1 (7%)       2 (14%)      1 (7%)       1 (7%)                                
   Tooth                                              (5)          (5)          (4)          (3)          (6)          (4)          
      Odontogenic Tumor                                5 (100%)     5 (100%)     3 (75%)      3 (100%)     6 (100%)     3 (75%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Spleen                                             (15)         (14)         (14)         (15)         (14)         (15)         
      Leukemia Erythrocytic                                                      1 (7%)                    1 (7%)       1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (14)         (15)         
      Keratoacanthoma                                                            3 (20%)                                            
      Squamous Cell Papilloma                          4 (27%)      1 (7%)       5 (33%)      2 (13%)      1 (7%)       1 (7%)      
      Squamous Cell Papilloma, Multiple                1 (7%)                    2 (13%)      1 (7%)       1 (7%)       3 (20%)     
      Conjunctiva, Squamous Cell Carcinoma                                                                 1 (7%)                   
      Lip, Squamous Cell Papilloma                                  1 (7%)       1 (7%)                                 1 (7%)      
      Lip, Squamous Cell Papilloma, Multiple           1 (7%)                                 1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (14)         (15)         (14)         (15)         
      Alveolar/Bronchiolar Adenoma                     1 (7%)                                 1 (7%)       2 (14%)                  
      Alveolar/Bronchiolar Carcinoma                                1 (7%)                                                          
      Carcinoma, Metastatic, Salivary Glands                                     1 (7%)                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
RESPIRATORY SYSTEM - cont                                                                                                           
      Leukemia Erythrocytic                                                      1 (7%)                                             
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                                                      1 (7%)                    1 (7%)       1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            11          10          11          11          12          10               
     Total Primary Neoplasms                           18          14          22          15          17          14               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  9           5           9           9           8           7               
     Total Benign Neoplasms                            13           7          17          11           9          10               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                           2           2           1           2           1               
     Total Malignant Neoplasms                                      2           2           1           2           1               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                      1                                                   
     Total Metastatic Neoplasm                                                  1                                                   
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  5           5           3           3           6           3               
     Total Uncertain Neoplasms                          5           5           3           3           6           3               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------